Prader-Willi syndrome: 2026 so far

DCCR had supportive results, while carbetocin did not show benefit in a large trial.

In the months covered, evidence for DCCR (Vykat XR) was strengthened by controlled withdrawal data and longer-term summaries. In the controlled withdrawal comparison, hyperphagia scores worsened after switching from DCCR to placebo. The withdrawal comparison also showed less weight gain over 16 weeks. In contrast, a large 12-week phase 3 trial (a late-stage trial testing whether a treatment works and is safe) found carbetocin nasal spray did not reduce hyperphagia scores more than placebo. Other related measures also did not separate. Across DCCR sources, fluid retention/edema (swelling from extra fluid) and hyperglycemia (high blood sugar) were repeatedly highlighted as safety issues that need monitoring. In the carbetocin summary, headache and fever were most commonly reported. In practical terms, these reports show that hunger effects can differ a lot by drug, and that safety monitoring is part of what gets tracked alongside hunger and weight.

Research covered in: January 2026, May 2026, July 2026

Small real-world reports suggested hunger scores may improve even when weight change is unclear.

In September, a small adult study linked semaglutide to lower hyperphagia scores and slowing of prior weight gain. Average weight change was not statistically significant in that group. Case-based evidence also described metabolic improvements with incretin-based medicines (hormone-based drugs that affect appetite and blood sugar) in individual adults. This included sequential retatrutide/oral semaglutide/dulaglutide in one person, and tirzepatide in another with limited follow-up data and adherence challenges. One earlier case-based report also included a person with PWS receiving dulaglutide with weight loss and reduced insulin requirements. Across the months covered, these small, non-randomized reports repeatedly showed that hunger-related outcomes and weight outcomes did not always move together. That means the early real-world signals are mainly about what might be possible, while questions remain about who benefits, how long effects last, and safety in broader PWS populations.

Research covered in: June 2026, September 2026

Longer follow-up showed that some weight regain can happen after early surgical weight loss.

In May, longer-horizon data described a 5-year retrospective comparison after sleeve gastrectomy (a weight-loss surgery that reduces stomach size) in PWS. Weight loss was greatest in the first 1 to 2 years. By year 5, it was only partly maintained. Weight loss was also less than in peers with non-syndromic obesity who had the same procedure. In that cohort, obesity-related comorbidities (other health problems linked to obesity) decreased on average after surgery. A lifestyle-only comparison group gained weight over time and had more comorbidities by 5 years. Separately, a single adult case report described substantial weight loss at 6 months after sleeve gastrectomy with an uneventful short-term recovery, while emphasizing uncertainty about long-term outcomes. In the months covered, this helps set expectations about the typical timing of weight change after surgery in PWS, while also showing that the evidence base is still limited outside small cohorts and case reports.

Research covered in: May 2026, June 2026

Some programs reported short-term changes in daily functioning along with metabolic measures.

In September, an interdisciplinary inpatient stabilization program for severe behavioral dysregulation (serious difficulty regulating emotions and behavior) in adolescents and young adults was followed by short-term improvements during the hospital stay. This included fewer aggressive incidents by the final week, better function, weight loss, and improved fasting metabolic markers. The design could not show what caused the changes. Also in September, a small-sample study of a sleep treatment package in children showed its clearest benefits around bedtime routines. Results were mixed across children for other sleep outcomes like night awakenings. Earlier in the year, observational work linked sensory processing differences (the way the brain handles everyday sights, sounds, and touch) to irritability in a 101-person dataset, suggesting measurable day-to-day sensory factors tracked with irritability levels. In the months covered, these reports highlight that studies often measure behavior, routines, and family functioning as outcomes in their own right, and those can shift even when weight is not the main or only signal.

Research covered in: April 2026, September 2026

Reports added detail on which sleep measurements lined up with risk signals in specific groups.

In June, a small monitored overnight study in 10 growth hormone-naive infants with central sleep apnea (pauses in breathing because the brain does not send steady signals) found supplemental oxygen reduced central apnea events and improved oxygen saturation measures. During monitoring, there was no clinically meaningful hypercapnia (too much carbon dioxide in the blood). In other months covered, several studies described PWS sleep-disordered breathing as complex. Reports included a mix of event types, lower oxygen levels, and a smaller heart-rate shift around obstructive events than matched controls. One small pediatric study reported pulmonary hypertension (high blood pressure in the lungs' arteries) in some children with PWS. In that cohort, hypoventilation (low breathing during sleep) was the factor linked to pulmonary hypertension. Separately, growth hormone-related sleep testing reports were mixed. One dataset suggested new sleep apnea after starting growth hormone occurred at similar rates across age groups. Another reported new obstructive sleep apnea in 5 of 25 children during growth hormone therapy. In the months covered, this adds detail on which sleep measures were tied to physiologic risk signals in certain cohorts, and it shows that sleep-breathing results can look different depending on what is measured and where testing is done.

Research covered in: January 2026, February 2026, March 2026, June 2026, August 2026